The demographics of ageing suggest a great need for an early diagnosis of dementia and for the development of preventive strategies. Neurodegeneration in Alzheimers disease is estimated to start 20-30 years before clinical onset, and the identification of biological markers for pre-clinical and early diagnosis is the principal aim of research studies in the field. In this book, the authors present topical research on Alzheimers diagnosis including cerebrospinal fluid biomarker Amyloid-B 1-42 identification; visual impairment in Alzheimers disease; cerebral glucose metabolism through F-fluoro-deoxy-glucose positron emission tomography and neuroimaging.
Preface; Quantitation of Amyloid-ß Oligomers in Human Body Fluids for Alzheimers Disease Early Diagnosis or Therapy Monitoring?; Visual Impairment in Alzheimer Disease:: Clinical, Pathophysiological & Instrumental Aspects; Alzheimers Disease Diagnosis:: A New Approach; Mitochondrial Haplogroups Associated with Japanese Alzheimers Patients; Leading Role & Limits of 18F-FDG-PET Imaging in Early Diagnosis of Alzheimers Disease; Artificial Neural Networks in Alzheimers Diagnosis:: A Perspective; Milestones & Difficulties in Alzheimers Disease Diagnosis; The Role of Neuroimaging in the Early Diagnosis of Alzheimers Disease; Cerebrospinal Fluid Biomarkers for Alzheimers Disease; Index.
Comments (0)
Your review appreciation cannot be sent
Report comment
Are you sure that you want to report this comment?
Report sent
Your report has been submitted and will be considered by a moderator.